Immunopotentiating activity of septilin.

Oral administration of septilin (100mg/animal/dose; five doses) was found to enhance natural killer cell mediated cytotoxicity and antibody-dependent cellular cytotoxicity in normal mice as well as tumour-bearing mice. Septilin treatment also activated the peritoneal macrophages which produced cytotoxicity to L929 cells. Septilin increased proliferation of bone-marrow cells and there was an increase in the number of alpha-naphthyl acetate esterase staining cells in the bone-marrow. In addition to the activation of cellular immunity, septilin was found to increase the number of antibody producing cells in the spleen and activation of antibody-dependent complement-mediated cell lysis. These studies justifies the use of this herbal preparation in improving immunocompetence in disease states.